Increase in Dividend and Quarterly Dividend Announced by Baxter

Published on: 03 May 2022
baxter-logo

The dividend was declared by the board of directors of Baxter and is due on July 1, 2022. The current indicated annual dividend rate per share of common stock is $1.16. When comparing this to the previous quarterly dividend rate of $0.28 per share, there has been an approximate 3.5% increase.

Leading global MedTech company Baxter International Inc. (NYSE: BAX) announced today that it will be increasing its quarterly cash dividend to $0.29 per share of common stock. Comparing this to the previous quarterly dividend rate of $0.28 per share, there has been an approximate 3.5% increase. The dividend was declared by the board of directors of Baxter and is due to stockholders of record on June 3, 2022, on July 1, 2022. The current indicated annual dividend rate per share of common stock is $1.16.

José (Joe) E. Almeida, chairman, president, and CEO of Baxter, said the company

"continues to advance its life-saving Mission and deliver value for shareholders amid an unprecedented healthcare landscape."

"We are happy to increase our dividend for the seventh year in a row thanks to our committed employees, diverse portfolio, and methodical capital allocation strategy. In order to benefit patients, caregivers, investors, and the numerous other stakeholder communities that depend on us, we will continue to concentrate on advancing innovation, accelerating growth, and realizing the potential of our Hillrom acquisition."

Baxter's market-leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital, and surgical products are relied upon every day by millions of patients, caregivers, and healthcare professionals at patient homes, hospitals, doctor's offices, and other sites of care. We have been in business for 90 years at the crucial crossroads where life-saving and life-sustaining innovations meet the healthcare professionals who make it happen. Baxter's employees worldwide are now building upon the company's rich history of medical breakthroughs to advance the next generation of transformative healthcare innovations, with products, digital health solutions, and therapies accessible in more than 100 countries. Visit www.baxter.com and follow us on Twitter, LinkedIn, and Facebook for more information.

Forward-looking statements about the company's capital allocation, which at the moment includes the payment of quarterly dividends, are included in this release. These predictions are based on numerous assumptions, so it's possible that Baxter's actual annual dividend payout rate will vary from the estimated annual indicative dividend described here, possibly significantly. Refer to Baxter's most recent Form 10-K filing and other SEC filings, all of which are accessible on Baxter's website, for details on some of the risks and significant factors that could have an impact on the company's future results, financial condition, and liquidity. Unless otherwise required by the federal securities laws, Baxter does not commit to updating its forward-looking statements.

Source: Baxter newsroom

Share:
esg
esg
esg
esg
More from Baxter International Inc.
Thurgood Marshall College Fund and Baxter International Foundation launch $3.5M minority student program
Thurgood Marshall College Fund and Baxter International Foundation launch $3.5M minority student program
Baxter completes the purchase of Hillrom, creating a $15 billion global leader in medical technology
Baxter completes the purchase of Hillrom, creating a $15 billion global leader in medical technology
Dow Jones Sustainability Indices Recognize Baxter's Corporate Responsibility
Dow Jones Sustainability Indices Recognize Baxter's Corporate Responsibility